JPMorgan Chase & Co. Increases Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $168.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target increased by analysts at JPMorgan Chase & Co. from $167.00 to $168.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 16.60% from the company’s current price.

A number of other research analysts also recently commented on the company. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Wedbush reiterated an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. UBS Group started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday. Finally, Oppenheimer lowered their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $193.43.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $144.08 on Thursday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The company has a 50 day simple moving average of $132.41 and a two-hundred day simple moving average of $132.36. The firm has a market cap of $8.74 billion, a P/E ratio of -17.83 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -7.12 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors have recently made changes to their positions in ASND. Signaturefd LLC increased its stake in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Ascendis Pharma A/S by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after buying an additional 4,338 shares during the period. Rice Hall James & Associates LLC increased its stake in shares of Ascendis Pharma A/S by 5.9% during the third quarter. Rice Hall James & Associates LLC now owns 160,614 shares of the biotechnology company’s stock valued at $23,981,000 after buying an additional 8,958 shares during the period. Pursue Wealth Partners LLC purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at $217,000. Finally, Harbor Capital Advisors Inc. increased its stake in shares of Ascendis Pharma A/S by 67.2% during the third quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company’s stock valued at $13,035,000 after buying an additional 35,102 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.